{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:58:35Z","timestamp":1794333515253,"version":"4.9.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MCUU00002\/15"],"award-info":[{"award-number":["MCUU00002\/15"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MCUU00040\/03"],"award-info":[{"award-number":["MCUU00040\/03"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The StratosPHere 2 trial will evaluate the efficacy of hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2 by focussing on the novel biomarker and other endpoints including safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study design<\/jats:title>\n            <jats:p>StratosPHere 2 is a three armed, placebo-controlled, phase 2 trial with two strata based on the mutation groups. It is response adaptive where the allocation of treatments follows a Bayesian response-adaptive randomisation algorithm. An expected number of 20 patients will be randomised in each stratum to one of the three arms containing hydroxychloroquine, phenylbutyrate and placebo. The primary outcome is a novel endpoint considering the change in the bone morphogenetic receptor type 2 (BMPR2).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>The final primary analysis on the efficacy of each active treatment against control is assessed using a one-sided nonparametric Wilcoxon test computed on the continuous biomarker data collected up to 8 weeks from the start of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>This manuscript presents the key elements of the StratosPHere 2 implementation and statistical analysis plan. This is submitted to the journal before the first interim analysis to preserve the scientific integrity under a response-adaptive design framework.<\/jats:p>\n            <jats:p>The StratosPHere 2 trial closely follows published guidelines for the content of Statistical Analysis Plans in clinical trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>The ISRCTN Registry ISRCTN10304915 (22\/09\/2023)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-08947-y","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:36:49Z","timestamp":1752230209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["StratosPHere 2: statistical analysis plan for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6225-4247","authenticated-orcid":false,"given":"Rajenki","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Deliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Toshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda S.","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"8947_CR1","unstructured":"NHS Digital. National audit of pulmonary hypertension: 12th annual report, 2020-21 Great Britain. 2022. Published 20 January 2022 (correction to survival analysis 18 July 2022). https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/national-pulmonary-hypertension-audit\/12th-annual-report. Accessed 18 Sep 2023."},{"key":"8947_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-015-0366-8","volume":"34","author":"K Coyle","year":"2016","unstructured":"Coyle K, Coyle D, Blouin J, Lee K, Jabr MF, Tran K, et al. Cost effectiveness of first-line oral therapies for pulmonary arterial hypertension: a modelling study. Pharmacoeconomics. 2016;34:509\u201320.","journal-title":"Pharmacoeconomics."},{"issue":"49","key":"8947_CR3","first-page":"1","volume":"13","author":"YF Chen","year":"2009","unstructured":"Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs J, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2009;13(49):1\u2013320.","journal-title":"Health Technol Assess (Winchester, England)."},{"issue":"16","key":"8947_CR4","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16):1478\u201390.","journal-title":"N Engl J Med."},{"issue":"18","key":"8947_CR5","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1093\/hmg\/ddt216","volume":"22","author":"BJ Dunmore","year":"2013","unstructured":"Dunmore BJ, Drake KM, Upton PD, Toshner MR, Aldred MA, Morrell NW. The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. Hum Mol Genet. 2013;22(18):3667\u201379.","journal-title":"Hum Mol Genet."},{"issue":"6","key":"8947_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1513\/pats.201002-024AW","volume":"7","author":"W Li","year":"2010","unstructured":"Li W, Dunmore BJ, Morrell NW. Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension. Proc Am Thorac Soc. 2010;7(6):395\u20138.","journal-title":"Proc Am Thorac Soc."},{"issue":"1","key":"8947_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/CIRCULATIONAHA.112.133413","volume":"127","author":"P Dromparis","year":"2013","unstructured":"Dromparis P, Paulin R, Stenson TH, Haromy A, Sutendra G, Michelakis ED. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation. 2013;127(1):115\u201325.","journal-title":"Circulation."},{"issue":"1","key":"8947_CR8","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1186\/s13063-024-08485-z","volume":"25","author":"N Deliu","year":"2024","unstructured":"Deliu N, Das R, May A, Newman J, Steele J, Duckworth M, et al. StratosPHere 2: study protocol for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2. Trials. 2024;25(1):680.","journal-title":"Trials."},{"issue":"26","key":"8947_CR9","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1200\/JCO.2011.39.8420","volume":"30","author":"L Trippa","year":"2012","unstructured":"Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, et al. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012;30(26):3258.","journal-title":"J Clin Oncol."},{"issue":"13","key":"8947_CR10","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/sim.6086","volume":"33","author":"JM Wason","year":"2014","unstructured":"Wason JM, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med. 2014;33(13):2206\u201321.","journal-title":"Stat Med."},{"issue":"24","key":"8947_CR11","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1002\/sim.4780142406","volume":"14","author":"S Senn","year":"1995","unstructured":"Senn S. A personal view of some controversies in allocating treatment to patients in clinical trials. Stat Med. 1995;14(24):2661\u201374.","journal-title":"Stat Med."},{"key":"8947_CR12","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2024. https:\/\/www.R-project.org\/."},{"key":"8947_CR13","unstructured":"Das R, Deliu N, Toshner M, Villar SS. Implementing response-adaptive randomisation in stratified rare-disease trials: design challenges and practical solutions.\u00a02024. https:\/\/arxiv.org\/abs\/2410.03346:2410.03346."},{"key":"8947_CR14","unstructured":"Sealed Envelope Ltd. Simple randomisation service. 2024. https:\/\/www.sealedenvelope.com\/simple-randomiser\/v1\/. Accessed 20 Mar 2025."},{"issue":"5","key":"8947_CR15","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1177\/0962280215597716","volume":"26","author":"J Bowden","year":"2017","unstructured":"Bowden J, Trippa L. Unbiased estimation for response adaptive clinical trials. Stat Methods Med Res. 2017;26(5):2376\u201388.","journal-title":"Stat Methods Med Res."},{"issue":"2","key":"8947_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/pst.1915","volume":"18","author":"S Unkel","year":"2019","unstructured":"Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, et al. On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies. Pharm Stat. 2019;18(2):166\u201383.","journal-title":"Pharm Stat."},{"issue":"23","key":"8947_CR17","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/jama.2017.18556","volume":"318","author":"C Gamble","year":"2017","unstructured":"Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dor\u00e9 C, et al. Guidelines for the content of statistical analysis plans in clinical trials. Jama. 2017;318(23):2337\u201343.","journal-title":"Jama."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08947-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08947-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08947-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:21:26Z","timestamp":1757222486000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08947-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8947"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08947-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was gained from London Surrey Borders on date 12\/09\/2023. Written, informed consent will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MRT received support from NIHR Cambridge BRC and MRC. He received consulting fees for advisory roles by Jansen, Apollo Therapeutics and Merck,\u00a0RxPx and uMEd, and travel support from GSK and Jansen. He has been member of the ComCov and FluCov data safety monitoring\/advisory boards. SSV is member of the advisory board for PhaseV.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}